Formulation study of PLGA in situ films for topical delivery of salicylates
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18470%2F24%3A50021501" target="_blank" >RIV/62690094:18470/24:50021501 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11160/24:10484398
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0939641124001085" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0939641124001085</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ejpb.2024.114282" target="_blank" >10.1016/j.ejpb.2024.114282</a>
Alternative languages
Result language
angličtina
Original language name
Formulation study of PLGA in situ films for topical delivery of salicylates
Original language description
A film -forming system (FFS) represents a convenient topical dosage form for drug delivery. In this study, a noncommercial poly(lactic-co-glycolic acid) (PLGA) was chosen to formulate an FFS containing salicylic acid (SA) and methyl salicylate (MS). This unique combination is advantageous from a therapeutic point of view, as it enabled modified salicylate release. It is beneficial from a technological perspective too, because it improved thermal, rheological, and adhesive properties of the in situ film. DSC revealed complete dissolution of SA and good miscibility of MS with the polymer. MS also ensures optimal viscoelastic and adhesive properties of the film, leading to prolonged and sustained drug release. The hydrolysis of MS to active SA was very slow at skin pH 5.5, but it apparently occurred at physiological pH 7.4. The film structure is homogeneous without cracks, unlike some commercial preparations. The dissolution study of salicylates revealed different courses in their release and the influence of MS concentration in the film. The formulated PLGA-based FFS containing 5 % SA and 10 % MS is promising for sustained and prolonged local delivery of salicylates, used mainly for keratolytic and antiinflammatory actions and pain relief.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
ISSN
0939-6411
e-ISSN
1873-3441
Volume of the periodical
199
Issue of the periodical within the volume
June
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
9
Pages from-to
"Article Number: 114282"
UT code for WoS article
001230330300001
EID of the result in the Scopus database
2-s2.0-85190355032